Both Europe and US regulators have strengthened pediatric regulations with the goal of increasing the availability of new drugs for children. When the disease in children is similar or related to an adult disease the pathway is much clearer. There are still challenges in developing new drugs for diseases that occur only in children. Efforts continue to help guide the development of pediatric medicines.
https://www.outsourcing-pharma.com/Article/2018/07/17/No-longer-an-option-Pediatric-considerations-in-drug-development
https://www.outsourcing-pharma.com/Article/2018/07/17/No-longer-an-option-Pediatric-considerations-in-drug-development
RSS Feed